Skip to main content
. 2019 Nov 21;2019(11):CD011931. doi: 10.1002/14651858.CD011931.pub2

Shepherd 2018.

Methods Study design: randomized controlled trial (2 arms)
Study duration: 2015 to 2016
Study setting: hospital, single centre, USA
Participants Adults participants undergoing transsphenoidal surgery for resection of pituitary tumours
Exclusion criteria
  1. Allergy or intolerance to acetaminophen, ibuprofen, or opioids

  2. Preoperative opioid tolerance, dependence, or abuse

  3. Anaphylaxis to opioids

  4. History of peptic ulcer disease or recent gastrointestinal bleed requiring surgery

  5. Cirrhosis, hepatitis, liver transplant, or abnormal liver function studies

  6. Subject unwilling or unable to sign informed consent for the study

  7. Pregnancy

  8. Incarcerated patients

  9. Non‐English speaking and literate or unable to understand the use of a pain scale

  10. Body Mass Index < 19 and > 40 kg/m2

  11. Renal failure


Mean age (years)
  1. 55


Numbers allocated to each arm
  1. Group intervention ‐ scheduled IV ibuprofen, scheduled oral acetaminophen, and rescue opioids

  2. Group control ‐ scheduled IV placebo, scheduled oral acetaminophen, and rescue opioids


Male gender
  1. Group intervention: 15/28

  2. Group control: 18/34

Interventions Technique and timing
  1. Intravenous ibuprofen versus placebo


Dosage
800 mg every 8 hours with the first dose given intraoperatively
Outcomes Primary
  1. Postoperative pain as measured by the VAS score measured every 4 hours to a max of 48 hours


Secondary
  1. Breakthrough narcotic requirement

  2. Total number of doses and type of any anti‐emetic required postoperatively in both groups

  3. The number of patients who did not have a bowel movement during hospitalization in both groups

  4. The number of patients in both groups with opioid‐associated adverse events, such as respiratory depression or sedation, using Pasero Opioid‐Induced Sedation Scale

  5. Total cost of hospital charges compared between 2 arms

  6. Other adverse events

  7. Cost of pharmacy charges compared between 2 arms

  8. Length of stay in hospital compared between 2 arms

  9. Adverse events

Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Quote:''Patients were randomised in a 1:1 ratio with blinded treatment assignment. The patients were randomised using a computer‐generated list of random numbers from www.random.org.''
Allocation concealment (selection bias) High risk Quotes:
''The randomised list was placed with an ordered list of numbers from 1 to 100. Odd numbers were assigned to Group 1 and even numbers to Group 2.''
''The research nurse generated the random number sequence and performed the blinded assignment''.
This implied that treatment allocation was predictable to the research nurse before the moment of allocation.
Blinding of participants and personnel (performance bias) 
 All outcomes Unclear risk Quote: ''Patients, family members, bedside nurses, and providers were blinded to treatment assignment. The treatment assignment was known by the research nurse and a research pharmacist''.
Blinding was neither well described nor complete.
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Not mentioned in the report who exactly assessed outcomes
Incomplete outcome data (attrition bias) 
 All outcomes Low risk All randomized patients were included in the analysis.
Selective reporting (reporting bias) Low risk Outcomes were reported as specified.
Other bias High risk The study was substantially underpowered for its primary outcome.
Quote:''Fifty treated patients in each group were required to detect a 2‐point MD on the 11‐point (0–10) VAS, with a standard deviation of 3.2 for the placebo group and 3.5 for the treatment group, with α set at 0.05 and 90% power.''